

This material is an English translation of the press release announced on July 21, 2020 in Japanese, and the Japanese release is given priority about the content and the interpretation.

July 21, 2020

**Notification of approval for manufacturing and marketing approval of
OABLOK® PATCH in Thailand
(Transdermal, Overactive bladder treatment patch)**

Hisamitsu Pharmaceutical Co., Inc. (Head Office: Tosu city, Saga Prefecture, Japan; President and CEO: Kazuhide Nakatomi, hereinafter referred to as “Hisamitsu Pharmaceutical”) announces that it has obtained approval of manufacturing and marketing for OABLOK® PATCH (Generic name: oxybutynin hydrochloride, hereinafter referred to as “the product”) in Thailand.

The product is a systemic transdermal formulation developed using Hisamitsu’s TDDS (Transdermal Drug Delivery System) technology for the treatment of overactive bladder with symptoms such as urinary urgency and frequent urination. Hisamitsu Pharmaceutical expects its long-lasting effect by means of maintaining a stable blood concentration, and the product to be a new option for treating overactive bladder in Thailand.

Hisamitsu Pharmaceutical launched the product under the product name “NEOXY® TAPE 73.5 mg” in Japan in June 2013, and under the product name “OABLOK® PATCH” in Taiwan in November 2019.

Hisamitsu Pharmaceutical will contribute to further improving the quality of life of patients who suffer from overactive bladder by providing proper information of the product.

Reference

Trade name	OABLOK® PATCH
Generic name	Oxybutynin hydrochloride
Indication	Overactive bladder with the symptoms of urinary urgency, frequent urination, and urge urinary incontinence
Dose and Administration	For usual adult dose, apply 1 patch (73.5 mg as oxybutynin hydrochloride) of this drug once daily to the lower abdomen, lower back, or thigh, and change the patch every 24 hours.